Evidence map›Paper›PMID 36134024›Full record

ArticleFrontiers in genetics2022

The role of ACE1 I/D and ACE2 polymorphism in the outcome of Iranian COVID-19 patients: A case-control study.

Arezoo Faridzadeh, Mahmoud Mahmoudi, Sara Ghaffarpour, Mohammad Saber Zamani, Akram Hoseinzadeh, Mohammad Mehdi Naghizadeh, Tooba Ghazanfari

Open access · goldAbstract read
In one paragraph

Article in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. The I/D variant of theFuture science OA · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Association betweenFrontiers in medicine · 2024
    Article
  9. Article
  10. Review
  11. TheInternational journal of molecular sciences · 2023
    Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Arezoo FaridzadehImmunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mahmoud MahmoudiImmunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Sara GhaffarpourImmunoregulation Research Center, Shahed University, Tehran, Iran.
Mohammad Saber ZamaniImmunoregulation Research Center, Shahed University, Tehran, Iran.
Akram HoseinzadehImmunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad Mehdi NaghizadehNoncommunicable Diseases Research Center, Fasa University of Medical Science, Fasa, Iran.
Tooba GhazanfariImmunoregulation Research Center, Shahed University, Tehran, Iran.
Mashhad University of Medical Sciences · IRShahed University · IRFasa University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

angiotensin-converting enzyme (ACE)coronavirus disease 2019 (COVID-19)insertion/deletionpolymorphismseveritySNP

Identifiers

PMID36134024
PMCPMC9483011
OpenAlexW4294627927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.